OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

HTML

Year: 2012
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-12-0868
Authors: Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber-Bodéré, Veronique Dieras, Max E. Scheulen, Avinash Gupta, Vanesa Lopez-Valverde, Zhi-Xin Xu, Ruediger Rueger, Jean J.L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jan H.M. Schellens, Wilfried Ernst Erich Eberhardt
Institutions: Inserm, Utrecht University, Churchill Hospital, The Netherlands Cancer Institute, University of Oxford, Essen University Hospital, Institut Curie
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: MEK inhibitors, MAPK/ERK pathway, advanced solid tumors, maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, pharmacodynamics, ERK1/2 phosphorylation, anticancer activity, RAS/RAF mutations, oral anticancer drugs, adverse events
SDG: Good health and well-being

Open Access status: closed

Funders: Roche, Chugai Pharmaceutical
OpenAlex ID: W2130979878
FWCI: 3.131
Cites: 50
Cited by: 73
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security